Document and Entity Information - shares |
6 Months Ended | |
|---|---|---|
Jun. 30, 2019 |
Aug. 01, 2019 |
|
| Document and Entity Information [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Period End Date | Jun. 30, 2019 | |
| Document Fiscal Year Focus | 2019 | |
| Document Fiscal Period Focus | Q2 | |
| Entity Registrant Name | AVENUE THERAPEUTICS, INC. | |
| Entity Central Index Key | 0001644963 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Shell Company | false | |
| Trading Symbol | ATXI | |
| Entity Common Stock, Shares Outstanding | 16,560,122 | |
| Entity Emerging Growth Company | true | |
| Entity Ex Transition Period | true | |
| Entity Small Business | true |
CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares |
Jun. 30, 2019 |
Dec. 31, 2018 |
|---|---|---|
| Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
| Preferred Stock, Shares Authorized | 2,000,000 | 2,000,000 |
| Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
| Common Stock, Shares Authorized | 50,000,000 | 50,000,000 |
| Common Stock, Shares, Issued | 16,559,747 | 10,667,714 |
| Common Stock, Shares, Outstanding | 16,559,747 | 10,667,714 |
| Series A Preferred Stock [Member] | ||
| Preferred Stock, Shares Issued | 250,000 | 250,000 |
| Preferred Stock, Shares Outstanding | 250,000 | 250,000 |
CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| Operating expenses: | ||||
| Research and development | $ 6,392 | $ 3,754 | $ 16,633 | $ 13,193 |
| General and administrative | 716 | 927 | 1,835 | 1,913 |
| Loss from operations | (7,108) | (4,681) | (18,468) | (15,106) |
| Interest income | (126) | (24) | (217) | (72) |
| Net Loss | $ (6,982) | $ (4,657) | $ (18,251) | $ (15,034) |
| Net loss per common share outstanding, basic and diluted | $ (0.43) | $ (0.45) | $ (1.21) | $ (1.48) |
| Weighted average number of common shares outstanding, basic and diluted | 16,314,763 | 10,251,950 | 15,035,811 | 10,176,062 |
Organization, Plan of Business Operations |
6 Months Ended |
|---|---|
Jun. 30, 2019 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 - Organization, Plan of Business Operations Avenue Therapeutics, Inc. (the “Company” or “Avenue”) was incorporated in Delaware on February 9, 2015, as a wholly owned subsidiary of Fortress Biotech, Inc. (“Fortress”), to develop and market pharmaceutical products for the acute care setting in the United States. The Company is focused on developing its product candidate, an intravenous (“IV”) formulation of tramadol HCI (“IV Tramadol”), for moderate to moderately severe post-operative pain. Stock Purchase and Merger Agreement On November 12, 2018, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”), entered into definitive agreements with two closing stages for a proposed acquisition of the Company for a total aggregate consideration of $215.0 million. The Stock Purchase and Merger Agreement (the “SPMA”) was approved by a majority of the Company’s stockholders, including a majority of its non-affiliated stockholders, at its special shareholder meeting on February 6, 2019. On February 8, 2019, InvaGen acquired 5,833,333 shares of the Company’s common stock at $6.00 per share (the “Stock Purchase Transaction”) for net proceeds of $31.5 million after deducting commission fees and other offering costs, representing a 33.3% stake in the Company’s capital stock on a fully diluted basis. At the second stage closing, InvaGen will acquire the remaining shares of Avenue’s common stock, pursuant to a reverse triangular merger with Avenue remaining as the surviving entity, for up to $180.0 million in the aggregate (the “Merger Transaction”). The second stage closing is subject to the satisfaction of certain closing conditions, including conditions pertaining to U.S. Food and Drug Administration approval, labeling, scheduling and the absence of any Risk Evaluation and Mitigation Strategy or similar restrictions in effect with respect to IV Tramadol, as well as the expiration of any waiting period applicable to the acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Subject to the terms and conditions described in the SPMA, InvaGen may also provide interim financing to the Company in an amount of up to $7.0 million during the time period between the Stock Purchase Transaction (which occurred on February 8, 2019) and the Merger Transaction. Any amounts drawn on the interim financing will be deducted from the aggregate consideration payable to the Company’s stockholders by virtue of the Merger Transaction. There have been no amounts drawn upon this interim financing as of June 30, 2019. Liquidity and Capital Resources The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future as it executes on its product development plan and may never become profitable. As of June 30, 2019, the Company had an accumulated deficit of $60.5 million. The Company believes that its cash and cash equivalents and short-term investments as of June 30, 2019, as well as its ability for interim financing of $7.0 million from InvaGen, will enable the Company to continue to fund operations in the normal course of business for more than a twelve-month period from the date of filing this Quarterly Report on Form 10‑Q. |
Significant Accounting Policies |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||
| Significant Accounting Policies [Text Block] | Note 2 — Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2018, which were included in the Company’s Form 10‑K, and filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2019. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. The Company has no subsidiaries. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 in its audited financial statements for the year ended December 31, 2018 included in the Company’s Form 10-K. With the exception of those noted below, there have been no material changes to the Company’s significant accounting policies. Short-term Investments The Company classifies certain of its certificates of deposit as short-term investments in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) ASC 320, Investments - Debt and Equity Securities. The Company considers all short-term investments with an original maturity in excess of three months but less than a year when purchased to be short-term investments. In May 2019, the Company purchased $5.0 million of certificates of deposit with an original maturity of six months. There were no investments as of December 31, 2018. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its certificates of deposit with an original maturity of six months should be classified as short-term investments as of June 30, 2019. This classification was based upon management’s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company’s certificates of deposit approximated fair value. Net loss per Share Loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options, during the period. Since dividends are declared paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. The following table sets forth the common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:
Recently Adopted Accounting Standards In June 2018, the FASB issued Accounting Standard Updated (“ASU”) No. 2018‑07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018‑07”), which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company adopted ASU 2018‑07 in the first quarter of 2019 and its adoption did not have a material impact on the Company’s unaudited condensed financial statements. |
||||||||||||||||||||||||||||||||||||||||
Related Party Agreements |
6 Months Ended |
|---|---|
Jun. 30, 2019 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions Disclosure [Text Block] | Note 3 — Related Party Agreements Management Services Agreement with Fortress Effective as of February 17, 2015, Fortress entered into a Management Services Agreement (the “MSA”) with Avenue to provide advisory and consulting services to Avenue for a period of five (5) years. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Avenue’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Avenue with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Avenue is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Avenue is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Avenue’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Avenue’s Board of Directors, have been contractually exempt from fiduciary duties to Avenue relating to corporate opportunities. In consideration for the Services, Avenue will pay Fortress an annual consulting fee of $0.5 million (the “Annual Consulting Fee”), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which Avenue has net assets in excess of $100.0 million at the beginning of the calendar year. Concurrently with the execution and delivery of the SPMA, the Company, InvaGen and Fortress entered into a Waiver Agreement, pursuant to which, among other things, Fortress irrevocably waived its right to receive dividends of the Company’s common shares under the terms of the Class A Preferred Stock and any fees, payments, reimbursements or other distributions under the MSA, until the termination of certain rights of InvaGen, pursuant to the Stockholders Agreement. For the three months ended June 30, 2019 and 2018, the Company had expenses related to the MSA of $0 and approximately $0.1 million, respectively. For the six months ended June 30, 2019 and 2018, the Company had expenses related to the MSA of $0 and approximately $0.3 million, respectively.
|
Accounts Payable and Accrued Expenses |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 4 — Accounts Payable and Accrued Expenses Accounts payable, accrued expenses and other liabilities consisted of the following (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note Disclosure [Text Block] | Note 5 — Stockholders’ Equity Stock Purchase Transaction On February 8, 2019, InvaGen acquired 5,833,333 shares of the Company’s common stock at $6.00 per share for net proceeds of $31.5 million after deducting commission fees and other offering costs, representing a 33.3% stake in the Company’s capital stock on a fully diluted basis. Equity Incentive Plan The Company has in effect the 2015 Incentive Plan (“2015 Incentive Plan”). The 2015 Incentive Plan was adopted in December 2015 by our stockholders. Under the 2015 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan authorizes grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant. Restricted Stock Units and Restricted Stock Awards The following table summarizes restricted stock unit and award activity for the six months ended June 30, 2019:
For the three months ended June 30, 2019 and 2018, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $0.5 million and $0.3 million, respectively. For the six months ended June 30, 2019 and 2018, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $1.3 million and $0.7 million, respectively. At June 30, 2019, the Company had unrecognized stock-based compensation expense related to restricted stock units and restricted stock awards of $1.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.5 years. This amount does not include, as of June 30, 2019, 341,173 shares of restricted stock outstanding which are performance-based and vest upon achievement of certain corporate milestones. The expense is recognized over the vesting period of the award. Stock-based compensation for milestone awards will be measured and recorded if and when it is probable that the milestone will be achieved. Stock Options The following table summarizes stock option award activity for the six months ended June 30, 2019:
Stock Warrants The following table summarizes the warrant activity for the six months ended June 30, 2019:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies (Policies) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||
| Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2018, which were included in the Company’s Form 10‑K, and filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2019. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. The Company has no subsidiaries. |
||||||||||||||||||||||||||||||||||||||||
| Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
||||||||||||||||||||||||||||||||||||||||
| Summary Of Significant Accounting [Policy Text Block] | Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 in its audited financial statements for the year ended December 31, 2018 included in the Company’s Form 10-K. With the exception of those noted below, there have been no material changes to the Company’s significant accounting policies. |
||||||||||||||||||||||||||||||||||||||||
| Investment, Policy [Policy Text Block] | Short-term Investments The Company classifies certain of its certificates of deposit as short-term investments in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) ASC 320, Investments - Debt and Equity Securities. The Company considers all short-term investments with an original maturity in excess of three months but less than a year when purchased to be short-term investments. In May 2019, the Company purchased $5.0 million of certificates of deposit with an original maturity of six months. There were no investments as of December 31, 2018. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its certificates of deposit with an original maturity of six months should be classified as short-term investments as of June 30, 2019. This classification was based upon management’s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company’s certificates of deposit approximated fair value. |
||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share, Policy [Policy Text Block] | Net loss per Share Loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options, during the period. Since dividends are declared paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. The following table sets forth the common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:
|
||||||||||||||||||||||||||||||||||||||||
| New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In June 2018, the FASB issued Accounting Standard Updated (“ASU”) No. 2018‑07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018‑07”), which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company adopted ASU 2018‑07 in the first quarter of 2019 and its adoption did not have a material impact on the Company’s unaudited condensed financial statements. |
||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||
| Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Expenses (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation, Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Plan of Business Operations (Details) - USD ($) $ / shares in Units, $ in Thousands |
Feb. 08, 2019 |
Jun. 30, 2019 |
Dec. 31, 2018 |
Nov. 12, 2018 |
|---|---|---|---|---|
| Accumulated deficit | $ (60,460) | $ (42,209) | ||
| Line of Credit [Member] | ||||
| Interim Financing Amount | $ 7,000 | $ 7,000 | ||
| Invagen Pharmaceuticals Inc [Member] | ||||
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 5,833,333 | |||
| Business Acquisition, Share Price | $ 6.00 | |||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 31,500 | $ 215,000 | ||
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 33.30% | |||
| Invagen Pharmaceuticals Inc [Member] | Common Stock [Member] | ||||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount | $ 180,000 |
Significant Accounting Policies (Details) - shares |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Total potential dilutive effect (in shares) | 1,400,162 | 943,332 | 1,400,162 | 943,332 |
| Restricted stock units/awards | ||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Total potential dilutive effect (in shares) | 1,150,162 | 673,332 | 1,150,162 | 673,332 |
| Preferred shares | ||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Total potential dilutive effect (in shares) | 250,000 | 250,000 | 250,000 | 250,000 |
| Options | ||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Total potential dilutive effect (in shares) | 20,000 | 20,000 | ||
Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 6 Months Ended |
|---|---|---|
May 31, 2019 |
Jun. 30, 2019 |
|
| Accounting Policies [Abstract] | ||
| Payments to Acquire Investments | $ 5,000 | $ 5,000 |
Related Party Agreements (Details) $ / yr in Millions, $ in Millions |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|---|
|
Feb. 17, 2017
USD ($)
$ / yr
|
Jun. 30, 2019
USD ($)
|
Jun. 30, 2018
USD ($)
|
Jun. 30, 2019
USD ($)
|
Jun. 30, 2018
USD ($)
|
|
| Majority Shareholder [Member] | |||||
| Related Party Transaction [Line Items] | |||||
| Service Agreement Expenses | $ 0.0 | $ 0.1 | $ 0.0 | $ 0.3 | |
| Asset Management Income [Member] | |||||
| Related Party Transaction [Line Items] | |||||
| Annual Consulting Fee | $ / yr | 0.5 | ||||
| Increase in Annual Consulting Fee | $ 1.0 | ||||
| Excess in Net Assets Value | $ 100.0 | ||||
Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands |
Jun. 30, 2019 |
Dec. 31, 2018 |
|---|---|---|
| Payables and Accruals [Abstract] | ||
| Accounts payable | $ 851 | $ 3,089 |
| Accrued employee compensation | 233 | 463 |
| Accrued contracted services and other | 644 | 1,117 |
| Accounts payable and accrued expenses | $ 1,728 | $ 4,669 |
Stockholders' Equity - Stock Purchase Transaction (Details) - Invagen Pharmaceuticals Inc [Member] - USD ($) $ / shares in Units, $ in Millions |
Feb. 08, 2019 |
Nov. 12, 2018 |
|---|---|---|
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 5,833,333 | |
| Business Acquisition, Share Price | $ 6.00 | |
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 31.5 | $ 215.0 |
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 33.30% |
Stockholders' Equity - Equity Incentive Plan (Details) - Two Thousand Fifteen Incentive Plan [Member] |
6 Months Ended |
|---|---|
|
Jun. 30, 2019
shares
| |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 2,000,000 |
| Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years |
| Options | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
| Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award | P10Y |
Stockholders' Equity - Restricted Stock Units and Restricted Stock Awards - Activity (Details) - Restricted stock units/awards |
6 Months Ended |
|---|---|
|
Jun. 30, 2019
$ / shares
shares
| |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
| Number of Units, Unvested Beginning Balance | shares | 1,104,643 |
| Number of Units, Granted | shares | 241,173 |
| Number of Units, Vested | shares | (195,654) |
| Number of Units, Unvested Ending Balance | shares | 1,150,162 |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
| Weighted Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares | $ 4.45 |
| Weighted Average Grant Date Fair Value, Granted | $ / shares | 5.93 |
| Weighted Average Grant Date Fair Value, Vested | $ / shares | 4.32 |
| Weighted Average Grant Date Fair Value, Unvested Ending Balance | $ / shares | $ 4.74 |
Stockholders' Equity - Restricted Stock Units and Restricted Stock Awards - Share-based Compensation Expense (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| Restricted stock units/awards | ||||
| Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
| Share-based Compensation | $ 0.5 | $ 0.3 | $ 1.3 | $ 0.7 |
Stockholders' Equity - Restricted Stock Units and Restricted Stock Awards - Unrecognized Share-based Compensation Expense (Details) - Restricted stock units/awards $ in Millions |
6 Months Ended |
|---|---|
|
Jun. 30, 2019
USD ($)
shares
| |
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract] | |
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $ | $ 1.7 |
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 6 months |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 341,173 |
Stockholders' Equity - Stock Options (Details) - $ / shares |
6 Months Ended | 12 Months Ended |
|---|---|---|
Jun. 30, 2019 |
Dec. 31, 2018 |
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ||
| Stock Options, Outstanding, Beginning | 20,000 | |
| Cancelled/forfeited | (20,000) | |
| Stock Options, Outstanding, Ending | 0 | 20,000 |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | ||
| Weighted Average Exercise Price, Outstanding, Beginning | $ 6.29 | |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | 6.29 | |
| Weighted Average Exercise Price, Outstanding, Ending | $ 0.00 | $ 6.29 |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] | ||
| Weighted Average Remaining Contractual Life | 3 years 7 months 17 days |
Stockholders' Equity - Warrants (Details) - Warrants under National Securities, Inc Note [Member] $ / shares in Units, $ in Thousands |
6 Months Ended | |
|---|---|---|
|
Jun. 30, 2019
USD ($)
$ / shares
shares
|
Dec. 31, 2018
USD ($)
|
|
| Class of Warrant or Right [Line Items] | ||
| Beginning Balance (in shares) | shares | 102,597 | |
| Exercised (in shares) | shares | (58,700) | |
| Ending Balance (in shares) | shares | 43,897 | |
| Aggregate Intrinsic Value | $ | $ 267 | $ 544 |
| Weighted Average [Member] | ||
| Class of Warrant or Right [Line Items] | ||
| Beginning Balance (in dollars per shares) | $ / shares | $ 0.0976 | |
| Exercised (in dollars per share) | $ / shares | 0.0001 | |
| Ending Balance (in dollars per shares) | $ / shares | $ 0.2279 |